https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0717-75262002000100007
EFECTOS DE LA METFORMINA EN EL SINDROME DE OVARIO POLIQUISTICO ASOCIADO A INSULINO RESISTENCIA

INTRODUCCION 

 

El Síndrome de ovario poliquístico (SOP) es una entidad clínica    caracterizada por anovulación crónica e hiperandrogenismo ovárico    funcional, LH e insulino dependiente. Es el desorden endocrino más común    de la mujer en edad reproductiva, con una prevalencia de un 5-10%. Representa    la causa más frecuente de infertilidad anovulatoria (50%) (1,    2) y de pérdida precoz de embarazos (82%) (4,    28).

 Se ha observado asociación de este síndrome con hiperinsulinismo    e insulino-resistencia en un 30 a 50% (1-28)    de las pacientes, jugando un rol clave en la etiopatogenia. El origen de esta    insulino-resistencia se encuentra no en un defecto congénito del receptor    de insulina sino, en un evento post-receptor. En 1995 Dunaif publica que el    problema es que ocurre una fosforilación de la serina, lo cual disminuye    la actividad de la tirosinquinasa, alterándose la traducción postreceptor    (21, 29). Este es un defecto genético    (21, 30). Finalmente la traducción    de la señal de insulina no es reconocida correctamente por los tejidos    blancos, a excepción del ovario, que utilizaría una vía    diferente de traducción (22, 260.    La insulino-resistencia periférica induce, en forma compensatoria, una    sobreproducción de insulina, la cual va a exacerbar sus efectos en los    tejidos insulino-sensibles.

 A nivel ovárico, la insulina, puede actuar a través de varias    vías (1, 2): 1) en sinergismo con LH,    2) estimulando su propio receptor en células tecales y del estroma ovárico,    3) a través de incrementar la síntesis de IGF-1 ó 4) utilizando    receptores de IGF-1 (receptor híbrido). Su acción provoca un aumento    de la síntesis ovárica de andrógenos, gracias a que induce    un incremento de la actividad de la enzima P450 17a    (11, 14, 15, 21,    24). Así mismo, la insulina estimula a la enzima P450    17a de células reticulares de la glándula    suprarrenal (13), aumentando la secreción de andrógenos    (DHEAS), potenciando la acción de ACTH. Por otra parte, la hiperinsulinemia    bloquea la síntesis hepática de SHBG y de IGFBP1, incrementando    los niveles de andrógenos libres (4).

 La metformina es una biguanida utilizada en el manejo de pacientes con diabetes    mellitus no insulino dependiente, capaz de aumentar la sensibilidad insulínica,    normalizando las glicemias sin riesgo de hipoglicemia. Su mecanismo de acción    es multifactorial, principalmente lo ejerce a nivel hepático donde disminuye    la gluconeogénesis o producción basal de glucosa. En la periferia    estimula la captación de glucosa por parte del músculo y el tejido    graso. No está claro si su efecto periférico deriva de mejorar    directamente la actividad postreceptor o tras incrementar el metabolismo no    oxidativo de la glucosa (11, 19).

 En el SOP la metformina ha sido utilizada tanto en pacientes obesas como delgadas    (3, 24). Conociendo la importancia de la    insulino-resistencia en la génesis de esta patología, han surgido    estudios que refieren que esta biguanida es capaz de disminuir el hiperandrogenismo    ovárico, mejorando los parámetros metabólicos endocrinos    y reproductivos de las pacientes (5, 7, 15,    27). Sin embargo, algunos investigadores refieren que estos    mismos efectos podrían obtenerse con la disminución de peso, que    ocasionalmente suele asociarse al uso de esta droga (3, 23,    26).

 El objetivo de nuestro estudio fue evaluar el efecto clínico, bioquímico    y reproductivo a corto plazo de la terapia con metformina en 11 pacientes con    SOP y además conocer los diversos parámetros predictivos de respuesta    a esta droga. 

 

MATERIAL Y METODOS 

 

Se estudian en forma prospectiva 11 pacientes con SOP que consultaron en la    unidad de Ginecología endocrinológica del Hospital San José.    La edad de las pacientes fluctuaron entre los 16 a 40 años.

 El criterio utilizado para definir SOP fue el descrito por Yen (2):    oligomenorrea y/o amenorrea desde la menarquia, hiperandrogenismo clínico    y/o bioquímico (hirsutismo, testosterona total mayor de 90 ng/dl y/o    testosterona libre mayor de 3,8 ng/ml) y niveles de gonadotrofinas alteradas    (LH aumentada sobre 10 mUI/ml o razón LH/FSH > 2,5). Para establecer    el diagnóstico de PCO bastan 2 de estos parámetros.

 Ciclos regulares se definieron como intervalos intermenstruales de 21-35 días.    Oligomenorrea se definió como menstruación con un intervalo mayor    a 35 días y menos de 8 ciclos/año. Amenorrea como la ausencia    de menstruaciones por más de 3 meses.

 El criterio para el diagnóstico de insulino-resistencia correspondió    a un hiperinsulinismo basal (> 20 mUI/ml) y a los 2 horas (> 60 mUI/ml)    luego de una prueba de sobrecarga a la glucosa oral (75 g), o el índice    de glicemia/insulinemia < 4,5.

 El protocolo de estudio consistió en la administración de metformina    1,7 g diarios dividida en 2 dosis, por vía oral. Todas las pacientes    fueron evaluadas en condiciones basales y después de recibir la droga    por 4 meses. En ambas oportunidades se les midió niveles plasmáticos    de FSH, LH, testosterona total y libre, SHBG, Prolactina, DHEAS, glicemia e    insulinemia y evaluación de volumen ovárico con ultrasonografía    transvaginal. Los exámenes fueron efectuados en fase folicular precoz,    o en cualquier momento en caso de amenorrea. Las pacientes se citaron mensualmente    al policlínico de endocrinología ginecológica donde se    les evaluó regularidad menstrual, peso, presión arterial, y score    de hirsutismo (Moncada). Se les solicitó que comunicaran espontáneamente    cualquier efecto adverso a la droga, siendo cada paciente su propio control.    Cinco pacientes que deseaban embarazo continuaron recibiendo la droga hasta    por un año, en una prueba abierta.

 Antes de incluirlas en el estudio se descartaron causas tumorales ováricas    y adrenales de hiperandrogenismo, hiperplasia suprarrenal congénita,    alteraciones tiroideas e hiperprolactinemias.

 Fueron excluidas del estudio las pacientes diabéticas y las que estaban    recibiendo terapia hormonal, anorexígenos o drogas que afectan el metabolismo    de las lipoproteínas en los 3 meses previo al estudio.

 El estudio fue aprobado por la Dirección del Hospital y las pacientes    aceptaron ingresar al estudio previo consentimiento informado.

 Para el análisis estadísticos se usó la prueba de Wilcoxon    para muestras pareadas. Se consideró un nivel de significancia estadística    para aquellos valores de P < 0,001. El análisis estadístico    se realizó usando el paquete computacional STATA versión 6.0.

 En la Tabla I, registramos la población en estudio.

 Todas las pacientes con SOP tenían oligoamenorrea. Se encontraron niveles    elevados de testosterona total y libre en el 42 y 57,1%, respectivamente; hirsutismo    (score de Moncada 7) en 6 de 11 pacientes (54%). Diez pacientes eran obesas,    91% del grupo de estudio, con IMC promedio de 35,2 kg/m2.

 Aunque no fue un criterio diagnóstico, 7 pacientes (64%) tenían    ovarios poliquísticos demostrados por ultrasonografía, con 8 o    más folículos subcapsulares de 3 a 8 mm de diámetro, con    aumento del estroma y del volumen ovárico bilateral (8 ml) (31).

 Para el análisis estadístico se usó la prueba de Wilcoxon    para muestras pareadas. Se consideró un nivel de significancia estadística    para aquellos valores de p < 0,001. El análisis estadístico    se realizó usando el paquete computacional STATA, versión 6.0.  

 

 

RESULTADOS 

 

Efectos clínicos (Tabla II) 

 

Al finalizar los cuatro meses de tratamiento 7 de 11 pacientes normalizaron    los ciclos menstruales (63,6%). En aquellas pacientes que se midió progesterona    en la fase media lútea los ciclos fueron ovulatorios. Tres de 5 mujeres    infértiles lograron embarazo (60%) al 5º y 7º mes de tratamiento.    Una de ellas presentó un aborto espontáneo a las 8 semanas y las    otras dos cursan embarazos fisiológicos. No hubo cambios en el score    de hirsutismo, índice de masa corporal ni de presión arterial,    al finalizar los 4 meses de tratamientos. Tampoco encontramos variaciones significativas    en el volumen ovárico promedio: 12,1 ml y 11,5 ml, durante la terapia    (p= 0,22). No se observaron modificaciones significativas en el perfil lipídico    de las pacientes al finalizar el tratamiento.

 Niveles hormonales de esteroides sexuales, gonadotrofinas e insulina (Tabla    III).

 Hubo una disminución significativa tanto de la insulinemia basal (48,7%)    como la de las dos horas postsobrecarga de glucosa (46,3%) y de la testosterona    libre (73,4%). Además encontramos un incremento significativo de los    niveles plasmáticos de SHBG (47%). Observamos una tendencia a la disminución    de la testosterona total.

 No encontramos variaciones en los niveles de glicemia y en el test de sobrecarga    a la glucosa oral, en ninguna de las pacientes, después del tratamiento    con metformina.

 En la Tabla IV dividimos a las pacientes en dos grupos,    según los cambios menstruales: exitosas (n= 7) y no exitosas (n= 4).    Observamos que ningún parámetro clínico o bioquímico    fue predictivo de respuesta a la metformina.

 No encontramos efectos adversos a la droga, excepto trastornos gastrointestinales    leves (náuseas, diarrea) que ocurrieron al inicio del tratamiento y que    no fue motivo de suspensión de este. 

 

Tabla I 

 

DATOS CLINICOS DE MUJERES CON SINDROME DE OVARIO POLIQUISTICO    n= 1

Edad (años) 25,5 ± 5,4 

% 

Obesidad      

10      

91      

Peso corporal (kg) =82 ± 13,1      

Hirsutismo      

6      

54,5      

Score hirsutismo=8 pts.      

(VN ­ 6)      

Infertilidad      

5      

46,5      

Oligomenorrea      

8      

72,7      

Amenorrea 2ª      

3      

27,3      

Acantosis 

9      

80      

nigricans 

Tabla II 

 

PATRON MENSTRUAL ANTES Y DURANTE LA TERAPIA CON METFORMINA    

  Previo 

 Previo 

Previo 

              Oligomenorrea      

 Oligomenorrea      

Oligomenorrea      

Tabla III 

 

CARACTERISTICAS CLINICAS, BIOQUIMICAS Y ULTRASONOGRAFICOS    EN PACIENTES EN SOP BASALES Y DURANTE EL TRATAMIENTO CON METFORMINA 

Previo al tratamiento        

       

X 

DS 

X 

Ds 

p 

IMC (kg lm2)      

35,2      

4,6      

34,1      

4,1      

0,53      

LH (u UI lml)      

11,2      

10,3      

10,2      

3,6      

0,68      

FSH (u Uli lml)      

5,4      

1,7      

5,6      

0,9      

0,71      

Insulinemia basal (u Ul/ml)      

39,8      

35,2      

20,4      

9,9      

0,06*      

Insulinemia (2 h)      

203,6      

112,6      

109      

54      

0,02*      

(u Ul/ml)      

Test total (ng/dl)      

95,6      

49,2      

47,3      

33,1      

0,22      

Test libre (ng/ml)      

7,9      

6,7      

2,1      

0,78      

0,06*      

DHEAS (ug/dl)      

235,4      

114      

150,9      

103,6      

0,46      

SHBG (nmol/lt)      

17      

3,9      

25      

11,5      

0,1*      

Volumen ovárico (ml)      

12,1      

7,7      

11,5      

6,1      

0,22      

Tabla IV 

 

NIVELES HORMONALES BASALES EN PACIENTES CON SOP RESPONDEDORES    Y     NO RESPONDEDORES A METFORMINA 

       

Respondedores 

n = 7 

n= 4 

p 

LH      

15,2      

(± 13)      

7      

Insulina basal      

28,3      

(±   6,9)      

51,2      

(±     4,9)      

0,9      

Insulina 2 horas      

207,7      

(± 83,1)      

198,7      

(± 151,8)      

0,46      

Test total      

79,5      

(± 45)      

117      

(±   54,9)      

0,15      

Test libre      

10,5      

(±   6,8)      

2,35      

(±     0,2)      

0,24      

DHEAS      

269,8      

(± 96,4)      

192,5      

(± 133,5)      

0,32      

IMC      

34,3      

(±   3,9)      

36,3      

(±     5,6)      

0,53      

DISCUSION 

 

Los hallazgos de este estudio demuestran que la metformina produce una reducción    en las concentraciones plasmáticas basales de testosterona total y libre    y de la secreción de DHEAS (marcador de andrógenos adrenales)    y un aumento de los niveles de SHBG circulantes, en mujeres con síndrome    de ovario poliquístico.

 Estos efectos son explicables por una disminución ocasionada por la    droga en los niveles plasmáticos de insulina basales como postsobrecarga    de glucosa. Mejora la resistencia insulínica, lo que ocasionaría    una disminución de la actividad de la enzima citocromo P450c17a    tanto de las células como adrenales. Estos efectos no pueden ser explicados    por una disminución de peso, como ha sido descrito por otros autores    (3, 23), ya que éste no se modificó    en el curso del tratamiento de nuestras pacientes.

 La disminución de la insulina reduce la frenación hepática    de la síntesis de SHBG por las células HEP G2 (18),    lo que provoca un aumento de las concentraciones plasmáticas de SHBG    y, a su vez, una disminución de los niveles de testosterona libre. Esto    mejoraría el microambiente intrafolicular (1, 2,    4), permitiendo un mejor desarrollo y crecimiento del folículo,    lo que lleva a ciclos ovulatorios, normalización de la función    menstrual y embarazo, como ocurrió en 3 de nuestras pacientes.

 No observamos modificaciones en los niveles plasmáticos de LH encontrados    por algunos autores (23, 26), pero no por    otros. Probablemente nuestras pacientes fueron poco respondedoras a este beneficio    descrito para la metformina debido a que presentaban obesidad severa (IMC >    35) (3, 9, 19, 26).

 Nuestro estudio, concordando con otros, demuestra que la metformina es capaz    de mejorar las anormalidades endocrinas, metabólicas y reproductivas    en pacientes con SOP (3-11, 13-31).

 Nuestro estudio, al igual que otros, demostró que el tratamiento con    metformina produjo una disminución significativa en los niveles de andrógenos    ováricos, concomitante con un descenso de la insulinemia. Creemos que    el factor etiopatogénico predominante en nuestras pacientes era dependiente    del hiperinsulinismo y no de LH.

 Este trabajo, a corto plazo, al igual que los otros investigadores no logró    demostrar mejoría del hirsutismo en las pacientes con SOP. Esto es explicable    por el tiempo que se requiere para actuar sobre el ciclo del crecimiento del    vello sexual, que es un mínimo de 3 meses, para lo cual se necesitaría    un mayor tiempo de observación para obtener alguna conclusión.

 Concordamos con la literatura que, con la disminución de la insulina    y del nivel de andrógenos, existe mayor número de ciclos ovulatorios    al mejorar el microambiente intrafolicular. Esto elimina el freno para el desarrollo    folicular normal (1, 2), logrando embarazo,    como aconteció en 3 de nuestras pacientes. De los embarazos, dos se obtuvieron    al 5º mes de tratamiento y el otro al 7º mes, luego de 2 meses de    terapia asociada a clomifeno. Dicha asociación, ha demostrado ser eficaz    en la inducción de ovulación de pacientes insulinorresistencia    refractarias a la terapia única con clomifeno (5, 7,    27).

 Ha sido demostrado que, en pacientes con SOP, la hiperinsulinemia afecta adversamente    la implantación del embrión al disminuir la glicodelina (factor    placenta-14) y la concentración de IGF BP1, proteínas producidas    en la glándulas endometriales. También afecta adversamente el    grosor y la vascularización endometrial, lo que puede ser medido por    ultrasonografía doppler. La metformina mejoraría las tasas de    implantación al acrecentar dichas proteínas y aumentar la vascularización    del endometrio. Se ha descrito que disminuye el índice de resistencia    de las arterias espirales en un 20% y mejora la penetración vascular    en un 19 a 69%, lo que finalmente resulta en una disminución de las tasas    de abortos precoces (4).

 Creemos que la metformina, dado su bajo costo, buena tolerancia y ausencia    de efectos adversos importantes, es una excelente droga a usar en pacientes    con SOP asociado a insulino resistencia, especialmente en aquellas con trastornos    metabólicos y dislipidemia. Además sería el fármaco    de primera línea como inductor de ovulación en pacientes infértiles    con este síndrome. 

 

BIBLIOGRAFIA 

 

 1. Speroff, Glass, Kase: Clinical gynecologic endocrinology    and infertility. Lippincott, USA: Williams and Wilkins 1999; Chapter 12.         [ Links ] 2. Yen, Jaffe, Barbieri: Reproductive endocrinology. USA:    WB Saunders & Co 1999; 443.         [ Links ] 3. Sir-Petermann, Alba, Castillo, Muñoz, Cortínez,    Maliqueo, Calvillán: Síndrome de ovario poliquístico: relación    entre sensibilidad tisular a la insulina, secreción de LH y cambios morfofuncionales    ováricos. Rev Méd Chile 1998; 126: 1049.         [ Links ] 4. Jakubowicz DJ, Seppala M, Jakubowicz S. y cols: Insulin    reduction with metformin increases luteal phase serum glycodelin and insulin    _like growth factor_ binding protein 1 concentrations and enhances uterine vascularity    and blood flow in the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2001; 86(3): 1126-33.         [ Links ] 5. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW,    Nestler JE: Metformin increase the ovulatory rate and pregnancy rate from clomiphene    citrate in patients with polycistic ovary syndrome who are resistant to clomiphene    citrate alone. USA: Fertil Steril 2001; 75(2): 310-5.         [ Links ] 6. Taylor AE: Insulin - lowering medications in polycystic    ovary syndrome. Obstet Gynecol Clin North Am 2000; 27(3): 583-95.         [ Links ] 7. Seale FG, Robinson RD, Neal GS: Association of metformin    and pregnancy in the polycystic ovary syndrome. A report of three cases. J Reprod    Med 2000; 45(6): 507.         [ Links ] 8. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A,    Martikainen HK, Tapanainen JS: Endocrine and metabolic effects of metformin    versus ethinyl estradiol-cyproterone acetate in obese women with polycystic    ovary syndrome: a randomize study. J Clin Endocrinol Metabol 2000; 85(9): 3161-8.          [ Links ] 9. Pasquali R, Gambineri A, Biscotti D y cols: Effect of long    - term treatment with metformin added to hypocaloric diet on body composition,    fat distribution, and androgen and insulin levels in abdominally obese women    with and without the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2000; 85(8): 2767-74.         [ Links ]10. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L:    Metformin therapy decrease hyperandrogenism and hyperynsulinemia in women with    polycystic ovary syndrome. Fertil Steril 2000; 73(6): 1149-54.         [ Links ]11. Diamanti-Kandarakis E, Zapati E: Insulin sensitizers and    antiandrogens in the treatment of polycystic ovary syndrome. Ann New York Acad    Scien 2000; 900: 203-12.         [ Links ]12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    R, Polonsky KS: The effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol    1999; 51(2): 231-6.         [ Links ]13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

 2. Yen, Jaffe, Barbieri: Reproductive endocrinology. USA:    WB Saunders & Co 1999; 443.         [ Links ] 3. Sir-Petermann, Alba, Castillo, Muñoz, Cortínez,    Maliqueo, Calvillán: Síndrome de ovario poliquístico: relación    entre sensibilidad tisular a la insulina, secreción de LH y cambios morfofuncionales    ováricos. Rev Méd Chile 1998; 126: 1049.         [ Links ] 4. Jakubowicz DJ, Seppala M, Jakubowicz S. y cols: Insulin    reduction with metformin increases luteal phase serum glycodelin and insulin    _like growth factor_ binding protein 1 concentrations and enhances uterine vascularity    and blood flow in the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2001; 86(3): 1126-33.         [ Links ] 5. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW,    Nestler JE: Metformin increase the ovulatory rate and pregnancy rate from clomiphene    citrate in patients with polycistic ovary syndrome who are resistant to clomiphene    citrate alone. USA: Fertil Steril 2001; 75(2): 310-5.         [ Links ] 6. Taylor AE: Insulin - lowering medications in polycystic    ovary syndrome. Obstet Gynecol Clin North Am 2000; 27(3): 583-95.         [ Links ] 7. Seale FG, Robinson RD, Neal GS: Association of metformin    and pregnancy in the polycystic ovary syndrome. A report of three cases. J Reprod    Med 2000; 45(6): 507.         [ Links ] 8. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A,    Martikainen HK, Tapanainen JS: Endocrine and metabolic effects of metformin    versus ethinyl estradiol-cyproterone acetate in obese women with polycystic    ovary syndrome: a randomize study. J Clin Endocrinol Metabol 2000; 85(9): 3161-8.          [ Links ] 9. Pasquali R, Gambineri A, Biscotti D y cols: Effect of long    - term treatment with metformin added to hypocaloric diet on body composition,    fat distribution, and androgen and insulin levels in abdominally obese women    with and without the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2000; 85(8): 2767-74.         [ Links ]10. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L:    Metformin therapy decrease hyperandrogenism and hyperynsulinemia in women with    polycystic ovary syndrome. Fertil Steril 2000; 73(6): 1149-54.         [ Links ]11. Diamanti-Kandarakis E, Zapati E: Insulin sensitizers and    antiandrogens in the treatment of polycystic ovary syndrome. Ann New York Acad    Scien 2000; 900: 203-12.         [ Links ]12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    R, Polonsky KS: The effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol    1999; 51(2): 231-6.         [ Links ]13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

 3. Sir-Petermann, Alba, Castillo, Muñoz, Cortínez,    Maliqueo, Calvillán: Síndrome de ovario poliquístico: relación    entre sensibilidad tisular a la insulina, secreción de LH y cambios morfofuncionales    ováricos. Rev Méd Chile 1998; 126: 1049.         [ Links ] 4. Jakubowicz DJ, Seppala M, Jakubowicz S. y cols: Insulin    reduction with metformin increases luteal phase serum glycodelin and insulin    _like growth factor_ binding protein 1 concentrations and enhances uterine vascularity    and blood flow in the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2001; 86(3): 1126-33.         [ Links ] 5. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW,    Nestler JE: Metformin increase the ovulatory rate and pregnancy rate from clomiphene    citrate in patients with polycistic ovary syndrome who are resistant to clomiphene    citrate alone. USA: Fertil Steril 2001; 75(2): 310-5.         [ Links ] 6. Taylor AE: Insulin - lowering medications in polycystic    ovary syndrome. Obstet Gynecol Clin North Am 2000; 27(3): 583-95.         [ Links ] 7. Seale FG, Robinson RD, Neal GS: Association of metformin    and pregnancy in the polycystic ovary syndrome. A report of three cases. J Reprod    Med 2000; 45(6): 507.         [ Links ] 8. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A,    Martikainen HK, Tapanainen JS: Endocrine and metabolic effects of metformin    versus ethinyl estradiol-cyproterone acetate in obese women with polycystic    ovary syndrome: a randomize study. J Clin Endocrinol Metabol 2000; 85(9): 3161-8.          [ Links ] 9. Pasquali R, Gambineri A, Biscotti D y cols: Effect of long    - term treatment with metformin added to hypocaloric diet on body composition,    fat distribution, and androgen and insulin levels in abdominally obese women    with and without the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2000; 85(8): 2767-74.         [ Links ]10. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L:    Metformin therapy decrease hyperandrogenism and hyperynsulinemia in women with    polycystic ovary syndrome. Fertil Steril 2000; 73(6): 1149-54.         [ Links ]11. Diamanti-Kandarakis E, Zapati E: Insulin sensitizers and    antiandrogens in the treatment of polycystic ovary syndrome. Ann New York Acad    Scien 2000; 900: 203-12.         [ Links ]12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    R, Polonsky KS: The effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol    1999; 51(2): 231-6.         [ Links ]13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

 4. Jakubowicz DJ, Seppala M, Jakubowicz S. y cols: Insulin    reduction with metformin increases luteal phase serum glycodelin and insulin    _like growth factor_ binding protein 1 concentrations and enhances uterine vascularity    and blood flow in the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2001; 86(3): 1126-33.         [ Links ] 5. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW,    Nestler JE: Metformin increase the ovulatory rate and pregnancy rate from clomiphene    citrate in patients with polycistic ovary syndrome who are resistant to clomiphene    citrate alone. USA: Fertil Steril 2001; 75(2): 310-5.         [ Links ] 6. Taylor AE: Insulin - lowering medications in polycystic    ovary syndrome. Obstet Gynecol Clin North Am 2000; 27(3): 583-95.         [ Links ] 7. Seale FG, Robinson RD, Neal GS: Association of metformin    and pregnancy in the polycystic ovary syndrome. A report of three cases. J Reprod    Med 2000; 45(6): 507.         [ Links ] 8. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A,    Martikainen HK, Tapanainen JS: Endocrine and metabolic effects of metformin    versus ethinyl estradiol-cyproterone acetate in obese women with polycystic    ovary syndrome: a randomize study. J Clin Endocrinol Metabol 2000; 85(9): 3161-8.          [ Links ] 9. Pasquali R, Gambineri A, Biscotti D y cols: Effect of long    - term treatment with metformin added to hypocaloric diet on body composition,    fat distribution, and androgen and insulin levels in abdominally obese women    with and without the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2000; 85(8): 2767-74.         [ Links ]10. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L:    Metformin therapy decrease hyperandrogenism and hyperynsulinemia in women with    polycystic ovary syndrome. Fertil Steril 2000; 73(6): 1149-54.         [ Links ]11. Diamanti-Kandarakis E, Zapati E: Insulin sensitizers and    antiandrogens in the treatment of polycystic ovary syndrome. Ann New York Acad    Scien 2000; 900: 203-12.         [ Links ]12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    R, Polonsky KS: The effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol    1999; 51(2): 231-6.         [ Links ]13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

 5. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW,    Nestler JE: Metformin increase the ovulatory rate and pregnancy rate from clomiphene    citrate in patients with polycistic ovary syndrome who are resistant to clomiphene    citrate alone. USA: Fertil Steril 2001; 75(2): 310-5.         [ Links ] 6. Taylor AE: Insulin - lowering medications in polycystic    ovary syndrome. Obstet Gynecol Clin North Am 2000; 27(3): 583-95.         [ Links ] 7. Seale FG, Robinson RD, Neal GS: Association of metformin    and pregnancy in the polycystic ovary syndrome. A report of three cases. J Reprod    Med 2000; 45(6): 507.         [ Links ] 8. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A,    Martikainen HK, Tapanainen JS: Endocrine and metabolic effects of metformin    versus ethinyl estradiol-cyproterone acetate in obese women with polycystic    ovary syndrome: a randomize study. J Clin Endocrinol Metabol 2000; 85(9): 3161-8.          [ Links ] 9. Pasquali R, Gambineri A, Biscotti D y cols: Effect of long    - term treatment with metformin added to hypocaloric diet on body composition,    fat distribution, and androgen and insulin levels in abdominally obese women    with and without the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2000; 85(8): 2767-74.         [ Links ]10. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L:    Metformin therapy decrease hyperandrogenism and hyperynsulinemia in women with    polycystic ovary syndrome. Fertil Steril 2000; 73(6): 1149-54.         [ Links ]11. Diamanti-Kandarakis E, Zapati E: Insulin sensitizers and    antiandrogens in the treatment of polycystic ovary syndrome. Ann New York Acad    Scien 2000; 900: 203-12.         [ Links ]12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    R, Polonsky KS: The effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol    1999; 51(2): 231-6.         [ Links ]13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

 6. Taylor AE: Insulin - lowering medications in polycystic    ovary syndrome. Obstet Gynecol Clin North Am 2000; 27(3): 583-95.         [ Links ] 7. Seale FG, Robinson RD, Neal GS: Association of metformin    and pregnancy in the polycystic ovary syndrome. A report of three cases. J Reprod    Med 2000; 45(6): 507.         [ Links ] 8. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A,    Martikainen HK, Tapanainen JS: Endocrine and metabolic effects of metformin    versus ethinyl estradiol-cyproterone acetate in obese women with polycystic    ovary syndrome: a randomize study. J Clin Endocrinol Metabol 2000; 85(9): 3161-8.          [ Links ] 9. Pasquali R, Gambineri A, Biscotti D y cols: Effect of long    - term treatment with metformin added to hypocaloric diet on body composition,    fat distribution, and androgen and insulin levels in abdominally obese women    with and without the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2000; 85(8): 2767-74.         [ Links ]10. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L:    Metformin therapy decrease hyperandrogenism and hyperynsulinemia in women with    polycystic ovary syndrome. Fertil Steril 2000; 73(6): 1149-54.         [ Links ]11. Diamanti-Kandarakis E, Zapati E: Insulin sensitizers and    antiandrogens in the treatment of polycystic ovary syndrome. Ann New York Acad    Scien 2000; 900: 203-12.         [ Links ]12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    R, Polonsky KS: The effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol    1999; 51(2): 231-6.         [ Links ]13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

 7. Seale FG, Robinson RD, Neal GS: Association of metformin    and pregnancy in the polycystic ovary syndrome. A report of three cases. J Reprod    Med 2000; 45(6): 507.         [ Links ] 8. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A,    Martikainen HK, Tapanainen JS: Endocrine and metabolic effects of metformin    versus ethinyl estradiol-cyproterone acetate in obese women with polycystic    ovary syndrome: a randomize study. J Clin Endocrinol Metabol 2000; 85(9): 3161-8.          [ Links ] 9. Pasquali R, Gambineri A, Biscotti D y cols: Effect of long    - term treatment with metformin added to hypocaloric diet on body composition,    fat distribution, and androgen and insulin levels in abdominally obese women    with and without the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2000; 85(8): 2767-74.         [ Links ]10. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L:    Metformin therapy decrease hyperandrogenism and hyperynsulinemia in women with    polycystic ovary syndrome. Fertil Steril 2000; 73(6): 1149-54.         [ Links ]11. Diamanti-Kandarakis E, Zapati E: Insulin sensitizers and    antiandrogens in the treatment of polycystic ovary syndrome. Ann New York Acad    Scien 2000; 900: 203-12.         [ Links ]12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    R, Polonsky KS: The effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol    1999; 51(2): 231-6.         [ Links ]13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

 8. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A,    Martikainen HK, Tapanainen JS: Endocrine and metabolic effects of metformin    versus ethinyl estradiol-cyproterone acetate in obese women with polycystic    ovary syndrome: a randomize study. J Clin Endocrinol Metabol 2000; 85(9): 3161-8.          [ Links ] 9. Pasquali R, Gambineri A, Biscotti D y cols: Effect of long    - term treatment with metformin added to hypocaloric diet on body composition,    fat distribution, and androgen and insulin levels in abdominally obese women    with and without the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2000; 85(8): 2767-74.         [ Links ]10. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L:    Metformin therapy decrease hyperandrogenism and hyperynsulinemia in women with    polycystic ovary syndrome. Fertil Steril 2000; 73(6): 1149-54.         [ Links ]11. Diamanti-Kandarakis E, Zapati E: Insulin sensitizers and    antiandrogens in the treatment of polycystic ovary syndrome. Ann New York Acad    Scien 2000; 900: 203-12.         [ Links ]12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    R, Polonsky KS: The effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol    1999; 51(2): 231-6.         [ Links ]13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

 9. Pasquali R, Gambineri A, Biscotti D y cols: Effect of long    - term treatment with metformin added to hypocaloric diet on body composition,    fat distribution, and androgen and insulin levels in abdominally obese women    with and without the polycystic ovary syndrome. USA: J Clin Endocrinol Metabol    2000; 85(8): 2767-74.         [ Links ]10. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L:    Metformin therapy decrease hyperandrogenism and hyperynsulinemia in women with    polycystic ovary syndrome. Fertil Steril 2000; 73(6): 1149-54.         [ Links ]11. Diamanti-Kandarakis E, Zapati E: Insulin sensitizers and    antiandrogens in the treatment of polycystic ovary syndrome. Ann New York Acad    Scien 2000; 900: 203-12.         [ Links ]12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    R, Polonsky KS: The effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol    1999; 51(2): 231-6.         [ Links ]13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

10. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L:    Metformin therapy decrease hyperandrogenism and hyperynsulinemia in women with    polycystic ovary syndrome. Fertil Steril 2000; 73(6): 1149-54.         [ Links ]11. Diamanti-Kandarakis E, Zapati E: Insulin sensitizers and    antiandrogens in the treatment of polycystic ovary syndrome. Ann New York Acad    Scien 2000; 900: 203-12.         [ Links ]12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    R, Polonsky KS: The effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol    1999; 51(2): 231-6.         [ Links ]13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

11. Diamanti-Kandarakis E, Zapati E: Insulin sensitizers and    antiandrogens in the treatment of polycystic ovary syndrome. Ann New York Acad    Scien 2000; 900: 203-12.         [ Links ]12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    R, Polonsky KS: The effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol    1999; 51(2): 231-6.         [ Links ]13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    R, Polonsky KS: The effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol    1999; 51(2): 231-6.         [ Links ]13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

13. La Marca A, Morgante G, Paglia T, Ciota L, Cianci A, De    Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic    ovary syndrome. Fertil Steril 1999; 72(6): 985.         [ Links ]14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

14. Paglia T, Cianci A, De Leo V, Cianci A: Metformin treatment    redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in    women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod    2000; 15(1): 21-3.         [ Links ]15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

15. Diamanti-Kandarakis E, Kouli C, Tsianatteli T, Bergiele    A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138: 269-74.         [ Links ]16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

16. Morghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo    M, Zanolin E, Muggeo M: Metformin effects on clinical features, endocrine and    metabolic profiles, and insulin sensitivity polycystic ovary syndrome: a randomized,    double-blind, placebo -controlled 6-month trial followed by open, long-term    clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-46.         [ Links ]17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

17. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic    ovary syndrome and metformin. Drugs 1999; (Suppl 1) 58: 41-6         [ Links ]18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

18. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen    HK: Metformin therapy improves the menstrual patterns with minimal endocrine    and metabolic effects in women with polycystic ovary syndrome. Fertil Steril    1998; 69(4): 691-6.         [ Links ]19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

19. Diamanti-Kandaris E, Kouli C, Tsianateli T, Bergiele:    Therapeutic effects of metformin on insulin resistance and hyperandrogenism    in polycystic ovary syndrome. Europ J Endocrinol 1998; 138(3): 269-74.         [ Links ]20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

20. Eharmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield    RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action,    and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin    Endocrinol Metabol 1997; 82(2): 524-30.         [ Links ]21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

21. Sozen I, Arici A: Hyperinsulinism and its interaction    with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000;    55(5): 321-28.         [ Links ]22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

22. Nestler JE, Kajubowicz DJ, Falcon de Vargas A, Brik C,    Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human    thecal cells from women with policystic ovary syndrome by activating its own    receptor and using inositolglycan mediators as the signal transduction system.    J Clin Endocrinol Metabol 1998; 83(6): 2001-05         [ Links ]23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

23. Velásquez E, Acosta A, Mendoza SG: Menstrual cyclicity    after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90(3):    392-94.         [ Links ]24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

24. Nestler JE, Jakubowicz DJ: Lean women with polycystyc    ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a    activity and serum androgens. J Clin Endocrinol Metabol 1997; 82(12): 4075-79.          [ Links ]25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

25. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence    and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance    in polycystic ovary syndrome: a prospective, controlled study in 254 affected    women. J Clin Endocrinol Metabol 1999; 84(1): 165-69.         [ Links ]26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

26. Luorno MJ, Nestler JE: The polycystic ovary syndrome:    treatment with insulin sensitizing agents. Diabetes, Obesity Metabolism 1999;    1: 127-36.        [ Links ]27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

27. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A: Effects    of metformin on gonadotropin-induced ovulation in women with polycystic ovary    syndrome. Fertil Steril 1999; 72(2): 282-85.         [ Links ]28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

28. Watson H, Kiddy DS, Hilton-Fairley D, Scanlon MJ, Barnard    C, Collins WP, Bonney RC, Franks S: Hypersecretion of luteinizing hormone and    steroids in women with recurrent early miscarriage. Human Reprod 1993; 8: 829-33.          [ Links ]29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

29. Dunaif A: Hyperandrogenic anovulation (PCOS): An unique    disorders of insulin action associated with an increase risk of non-insulin-dependent    diabetes mellitus. Am J Med 1995; 98(S): 33-39.         [ Links ]30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

30. Taylor SI, Cama A, Accili D et al: Mutation in    insulin receptor gene. Endocrinol Rev 1992; 13: 566-95.         [ Links ]31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  

31. Franks S: Polycystic ovary síndrome. New Engl J    Med 1995; 333: 853.        [ Links ]*Trabajo recibido en noviembre de 2001 y aceptado para publicación    por el Comité Editor en febrero de 2002.  